Group 1 - Strive Asset Management, LLC (NASDAQ:ASST) experienced a price surge of 7.03% on Wednesday, closing at $0.8620, as investors increased their positions following a failure to meet exchange listing requirements [1][4] - The company has been trading below the $1 minimum bid price for 10 consecutive days since December 11, 2025, which raises concerns about potential delisting from the Nasdaq [2] - Strive announced an increase in its annual dividend rate for preferred stockholders to 12.25% from 12%, with monthly payments starting in January 2026 [2][3] Group 2 - The first round of dividends, amounting to $1.0208 per share, will be payable on January 15, 2026, to preferred shareholders recorded as of January 1, 2026 [3] - Strive Asset Management holds approximately 7,525 Bitcoins as of November 7, 2025, positioning itself as a Bitcoin treasury company [4]

Carnival Corporation & plc (NYSE:CCL) is one of the best high volume stocks to buy right now. On December 22, Wells Fargo analyst Trey Bowers raised the firm’s price target on Carnival to $38 from $35 while keeping an Overweight rating on the shares. This decision was posted after the company announced its Q4 2025 earnings report. Carnival successfully addressed investor anxiety regarding 2026 yields and rising Caribbean competition by issuing strong yield growth guidance. The company’s projected EPS surpa ...

Core Viewpoint - LyondellBasell Industries N.V. is facing significant challenges in the chemicals sector, with a downgrade from Wells Fargo reflecting a cautious outlook for the industry through at least the first half of 2026 [2]. Financial Performance - In Q3, LyondellBasell reported revenue of $7.73 billion, a decrease of 10% year-over-year, and an EBITDA loss of $835 million compared to a profit of $1.17 billion in the same quarter last year [3]. - The company's stock has declined nearly 41% in 2025, attributed to higher raw material costs, soft demand, and increased competition [3]. Cash Management - Despite the pressures, LyondellBasell achieved a cash conversion rate of 135% in Q3, indicating progress in its cash improvement plan [4]. - Operating cash flow for the quarter was $983 million, with $443 million returned to shareholders through dividends, demonstrating confidence in the balance sheet [5]. - The company aims to generate $600 million in cash flow in 2025 and at least $1.1 billion by the end of 2026 [4]. Market Conditions - The chemicals sector is experiencing "trough-like conditions," with slow recovery in China and weak housing markets in the U.S. and Europe impacting demand [2].

Group 1 - UniQure (NASDAQ:QURE) is considered a promising small-cap stock with significant upside potential, despite recent price target reductions by analysts [1][2] - Stifel reduced its price target for UniQure from $50 to $40 while maintaining a Buy rating, citing refreshed diligence on biotechnology companies [1] - Mizuho analyst Uy Ear lowered the price target from $60 to $33 but kept an Outperform rating, indicating a decreased probability of success for the company's AMT-130 therapy [2] Group 2 - UniQure announced on December 4 that it received final meeting minutes from the FDA regarding the pre-Biologics License Application (BLA) meeting for AMT-130, an investigational gene therapy for Huntington's disease [3] - The FDA indicated that the data from Phase I/II studies of AMT-130 is unlikely to support a BLA submission, prompting UniQure to plan a follow-up meeting with the FDA for fiscal Q1 2026 [4] - UniQure focuses on developing innovative gene therapies for conditions such as Huntington's disease, hemophilia, and cardiovascular issues [5]

Core Insights - Rising private healthcare costs are prompting millionaires to reconsider their living locations, as highlighted by Henley & Partners [1] Inflation Concerns - Inflation is a significant concern, with fears that it could spiral out of the Federal Reserve's control by 2026 [2][5] - Recent data indicates that while headline inflation was cooler than expected in November, it remains above the Fed's 2% target [3] Stock Market Observations - The stock market is perceived to be in a bubble, with the "Dr. X's Bubble Detector" indicating all-time high equity prices [3][5] Money Supply Dynamics - The M2 money supply has increased by $3.5 trillion over the past five years, which is viewed as a critical metric for inflation outlook [4] - The Federal Reserve's recent actions, including rate cuts and the cessation of quantitative tightening, are expected to loosen financial conditions, potentially accelerating price growth [6] Factors Contributing to Inflation - Several developments are identified that could exacerbate inflation in the coming year: 1. Fed rate cuts that loosen financial conditions [6] 2. The end of quantitative tightening, which previously aimed to control inflation [6] 3. Easing of lending rules, allowing banks to increase the money supply [7] 4. Increased issuance of T-bills by the US Treasury to fund government deficits, contributing to inflationary pressures [7]

Core Insights - UnitedHealth Group has sold its last remaining business in South America, Banmedica, to Patria Investments for $1 billion [2] - The company has been exiting Latin America since 2022, with Banmedica being the final asset after previous sales in Brazil and Peru [3] - The exit from South America is part of CEO Stephen Hemsley's strategy to refocus the business [4] Financial Performance - UnitedHealth raised its annual profit forecast in October and anticipates growth to return in 2026, with momentum expected to build in 2027 [5] - The company incurred an $8.3 billion loss related to its South American exits, with $7.1 billion attributed to Brazil and $1.2 billion linked to Banmedica [5] Business Operations - Banmedica served approximately 1.7 million health insurance members and operated seven hospitals and 47 medical centers prior to the sale [4] - UnitedHealth operates primarily through two units: UnitedHealthcare and Optum, which encompass insurance, care delivery, data, and health services [6]

Seema Shah, Principal Asset Management chief global strategist, discusses how she sees the macroeconomic landscape for markets in 2026 and the outlook for AI stocks on "Bloomberg Open Interest." ...

We recently published 10 Stocks Facing Selling Pressure Ahead of Christmas. USA Rare Earth, Inc. (NASDAQ:USAR) is one of the biggest losers on Monday. USA Rare Earth dropped its share prices by 12.73 percent on Monday to finish at $14.87 apiece, mirroring the drop in the industry and the broader market, after the Trump administration selected a non-US-based firm as a partner to ramp up zinc production in the US. According to Reuters, the Trump administration, through a joint venture company it formed wit ...

Core Viewpoint - Solid Biosciences Inc. is positioned as a strong investment opportunity, particularly with its SGT-003 gene therapy, following safety concerns regarding Sarepta's Elevidys treatment for Duchenne muscular dystrophy [1][3]. Financial Performance - In Q3 2025, Solid Biosciences reported a cash position of $236.1 million, an increase from $148.9 million at the end of 2024, which is expected to fund operations into H1 2027 [2]. - The company experienced a net loss of $45.8 million in Q3 2025, up from $32.7 million in Q3 2024, primarily due to increased R&D expenses related to the SGT-003 program [2]. Clinical Development - The SGT-003 trial (INSPIRE DUCHENNE) demonstrated strong efficacy, with a mean microdystrophin expression of 58% among 10 participants evaluated at Day 90, and the therapy was well tolerated [3]. - As of October 31, 2025, 23 participants have been dosed, and the company plans to meet with the FDA in H1 2026 to discuss accelerated approval pathways after starting the Phase 3 IMPACT DUCHENNE trial [3]. - Solid Biosciences is also advancing its pipeline with new Phase 1b trials for SGT-212 and SGT-501, set to begin in Q4 2025 [3]. Company Overview - Solid Biosciences develops therapies for neuromuscular and cardiac diseases in the US and is involved in creating platform technologies, including capsid libraries and genetic regulators [4].

McDonald’s Corporation (NYSE:MCD) is among the 12 Best Performing Dow Stocks in 2025.  Barclays Analyst A Buy Rating On McDonald’s Corporation (MCD) Barclays analyst Jeff Bernstein kept a Buy rating on McDonald’s Corporation (NYSE:MCD) on December 6 and set a price goal of $358. According to a December 8 CNBC report, starting on January 1, 2026, McDonald’s Corporation (NYSE:MCD) will evaluate franchisees worldwide based on how well their prices provide value in accordance with revised global franchising ...